Scarica l'app Stockscreener
1.41
2.92%
0.04
Dopo l'orario di chiusura:
1.38
-0.03
-2.13%
Precedente Chiudi:
$1.37
Aprire:
$1.39
Volume 24 ore:
260.13K
Relative Volume:
0.16
Capitalizzazione di mercato:
$48.48M
Reddito:
-
Utile/perdita netta:
$-16.14M
Rapporto P/E:
-2.6111
EPS:
-0.54
Flusso di cassa netto:
$-3.99M
1 W Prestazione:
-2.76%
1M Prestazione:
-1.40%
6M Prestazione:
-19.89%
1 anno Prestazione:
-68.94%
Intervallo 1D:
$1.36
$1.41
Intervallo di 1 settimana:
$1.34
$1.48
Portata 52W:
$1.12
$5.40
Telomir Pharmaceuticals Inc Stock (TELO) Company Profile
Nome
Telomir Pharmaceuticals Inc
Settore
Industria
Telefono
786-396-6723
Indirizzo
100 SE 2ND ST, MIAMI
Confronta TELO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TELO
Telomir Pharmaceuticals Inc
|
1.41 | 47.10M | 0 | -16.14M | -3.99M | -0.54 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.20 | 113.51B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
767.96 | 78.69B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.23 | 52.32B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
854.99 | 52.15B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
174.84 | 35.52B | 447.02M | -1.18B | -906.14M | -6.1812 |
Telomir Pharmaceuticals Inc Stock (TELO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-21 | Iniziato | Rodman & Renshaw | Buy |
Telomir Pharmaceuticals Inc Borsa (TELO) Ultime notizie
How institutional buying supports Telomir Pharmaceuticals Inc. stock2025 Trading Recap & Verified Entry Point Signals - Улправда
Will Telomir Pharmaceuticals Inc. stock benefit from sector rotation2025 Technical Patterns & Weekly Breakout Stock Alerts - Улправда
How Telomir Pharmaceuticals Inc. stock reacts to oil pricesJuly 2025 Pullbacks & Reliable Price Breakout Alerts - DonanımHaber
Whale Trades: Is Telomir Pharmaceuticals Inc. stock a top momentum play2025 Market Outlook & Community Shared Stock Ideas - Улправда
Why analysts remain bullish on Telomir Pharmaceuticals Inc. stockTreasury Yields & Community Consensus Picks - Улправда
Can Telomir Pharmaceuticals Inc. stock sustain revenue growthJuly 2025 Trends & Capital Efficiency Focused Strategies - Улправда
Is Telomir Pharmaceuticals Inc. stock positioned for digital transformationJuly 2025 PostEarnings & Community Driven Trade Alerts - Улправда
Telomir Pharmaceuticals Reports Favorable IND-Enabling GLP Safety Results for Telomir-1 Supporting First-in-Human Clinical Development - ACCESS Newswire
Is Telomir Pharmaceuticals Inc. stock a top momentum playJuly 2025 Action & Accurate Buy Signal Alerts - Улправда
Telomir Pharmaceuticals Reports Positive IND-Enabling Study Results - TipRanks
TELO Stock Jumps Pre-market After Early Study Results Show Leukemia Cell Death - MSN
Telomir Pharmaceuticals Reports New Data Showing Telomir-1 Significantly Reduces PSA Levels in Human Prostate Cancer Cells - USA Today
Telomir Pharmaceuticals Reports Discovery That Telomir-1 Selectively Kills Aggressive Triple-Negative Breast Cancer Cells - Daily Commercial
Telomir Pharmaceuticals Inc. (TELO) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Why Telomir Pharmaceuticals Inc. stock attracts high net worth investorsTrade Signal Summary & Free Community Supported Trade Ideas - Newser
Telomir Pharmaceuticals (NASDAQ:TELO) Shares Up 2.3% – Still a Buy? - Defense World
Telomir Pharmaceuticals announces new preclinical data on Telomir-1 - MSN
Telomir and Mira Pharmaceuticals advance through key development milestones with Recipharm support - marketscreener.com
Telomir Pharmaceuticals Unveils Promising Preclinical Cancer Data - MSN
Telomir reports PSA reduction in prostate cancer cells with lead drug - Investing.com Nigeria
Telomir reports PSA reduction in prostate cancer cells with lead drug By Investing.com - Investing.com South Africa
Telomir Pharmaceuticals Reports Promising Preclinical Data - TipRanks
[8-K] Telomir Pharmaceuticals, Inc. Reports Material Event | TELO SEC FilingForm 8-K - Stock Titan
Telomir Pharmaceuticals Announces Telomir-1 Kills Aggressive Human Leukemia Cells - Bluffton Today
Will Telomir Pharmaceuticals Bounce Back? - StocksToTrade
Telomir Pharmaceuticals (TELO) Unveils Leukemia Breakthrough and Board Change – Full Investor Update for November 21, 2025 - ts2.tech
Telomir stock surges after leukemia cell-killing data By Investing.com - Investing.com Nigeria
Telomir stock surges after leukemia cell-killing data - Investing.com UK
Telomir Pharma (NASDAQ: TELO) Telomir-1 Shows Preclinical HL60 Leukemia Activity - Stock Titan
Telomir Pharmaceuticals director Craig Eagle resigns from board By Investing.com - Investing.com Australia
Telomir Pharmaceuticals director Craig Eagle resigns from board - Investing.com
Telomir Pharmaceuticals Inc. Announces Resignation of Craig Eagle as Director, Effective on November 14, 2025 - MarketScreener
Telomir Pharmaceuticals’ Telomir-1 Shows Leukemia Efficacy - TipRanks
Telomir Pharmaceuticals, Inc. Announces Telomir-1 Kills Aggressive Human Leukemia Cells - marketscreener.com
How Telomir Pharmaceuticals Inc. stock performs after earnings2025 Market Overview & Precise Buy Zone Tips - newser.com
Does Telomir Pharmaceuticals Inc. stock trade at a discount to peersQuarterly Portfolio Summary & Daily Stock Trend Watchlist - newser.com
Telomir Pharmaceuticals Inc Azioni (TELO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.44%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):